文献速递乳腺癌

Bireociclib联合氟维司群治疗内分泌进展后晚期乳腺癌:BRIGHT-2 3期随机临床试验

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

BRIGHT-2最终分析纳入305例HR阳性/HER2阴性晚期乳腺癌患者,2:1随机接受bireociclib+氟维司群或安慰剂+氟维司群。

要点

  • bireociclib联合氟维司群较安慰剂显著延长PFS(14.7 vs 7.3个月,HR 0.54)。
  • ORR在bireociclib组为45.6%,安慰剂组为14.9%。
  • 安全性特征与已知CDK4/6抑制剂一致,不良事件可控。

核心结论

  • 在HR阳性、ERBB2阴性晚期乳腺癌内分泌治疗后进展患者中,bireociclib联合氟维司群较安慰剂联合氟维司群显著改善PFS,且安全性可控。

研究设计与样本

  • 双盲、安慰剂对照3期随机临床试验,在中国64家医院开展,入组305例患者,按2:1随机分配至bireociclib+氟维司群组(n=204)或安慰剂+氟维司群组(n=101)。
  • 患者中位年龄54.1岁(SD 10.2),数据截止时中位随访19个月(IQR 18.5-19.6),275例(90.2%)有可测量病灶,268例(87.9%)既往接受过全身化疗。

主要发现

  • bireociclib组ORR为45.6%(95%CI 38.6-52.7),安慰剂组为14.9%(95%CI 8.6-23.3)。
  • bireociclib组中位缓解持续时间未达到(95%CI 11.1-未达到),安慰剂组为13.1个月(95%CI 10.2-未达到)。
  • 亚组分析(绝经状态、转移部位、既往治疗、无病间期、ESR1/PIK3CA/TP53变异等)显示bireociclib组PFS改善一致。
  • 出现早期腹泻的患者似乎从bireociclib治疗中获益更多(HR 0.49,95%CI 0.36-0.68)。

临床怎么用

  • 对于HR阳性、ERBB2阴性晚期乳腺癌内分泌治疗后进展的患者,可考虑bireociclib联合氟维司群作为治疗选择。
  • 治疗期间应监测不良事件,安全性特征与已知CDK4/6抑制剂一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The BRIGHT-2 interim analysis demonstrated the efficacy of bireociclib plus fulvestrant in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (ERBB2; previously HER2)-negative advanced breast cancer (ABC) after endocrine therapy progression. This final analysis includes an additional 11-month follow-up. OBJECTIVE: To evaluate the efficacy and safety of bireociclib plus fulvestrant in HR-positive, ERBB2-negative ABC. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled phase 3 randomized clinical trial was conducted at 64 hospitals in China between December 8, 2021, and October 24, 2022. Patients were enrolled and randomly assigned in a 2:1 to receive bireociclib plus fulvestrant or placebo plus fulvestrant. Data were analyzed from April 2024 to December 2025. INTERVENTIONS: Patients received bireociclib, 360 mg, or placebo orally every 12 hours in combination with fulvestrant, 500 mg, intramuscularly (days 1 and 15 of cycle 1, then day 1 of each 28-day cycle). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included overall survival, objective response rate, duration of response, and safety. RESULTS: Of 305 included patients, the mean (SD) age was 54.1 (10.2) years, and the median (IQR) follow-up at data cutoff was 19 (18.5-19.6) months. Patients were randomized to bireociclib plus fulvestrant (n = 204) or placebo plus fulvestrant (n = 101); 275 (90.2%) had measurable disease and 268 (87.9%) had received prior systemic chemotherapy. Bireociclib plus fulvestrant significantly prolonged PFS vs placebo (median PFS, 14.7 months [95% CI, 11.1-20.2] vs 7.3 months [95% CI, 5.5-11.0]; hazard ratio, 0.54; 95% CI, 0.40-0.74; P < .001). The objective response rate was higher (45.6% [95% CI, 38.6-52.7] vs 14.9% [95% CI, 8.6-23.3]) in the bireociclib group, with a prolonged median duration compared with placebo (not reached [95% CI, 11.1 to not reached] vs 13.1 months [95% CI, 10.2 to not reached]). Safety was consistent with the interim findings and the profiles of known cyclin-dependent kinase 4/6 inhibitors. Subgroup analyses across multiple patient characteristics (menopausal status, metastatic sites, prior treatment, disease-free interval, ESR1/PIK3CA/TP53 alterations and others) showed consistent PFS improvements with bireociclib vs placebo. Patients with early-onset diarrhea appeared to derive more benefit from bireociclib (hazard ratio, 0.49; 95% CI, 0.36-0.68). CONCLUSIONS AND RELEVANCE: The final analysis of the BRIGHT-2 randomized clinical trial confirms improved PFS with the addition of bireociclib to fulvestrant, with manageable safety as a treatment option for patients with HR-positive, ERBB2-negative ABC with progression after prior endocrine therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05077449.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhang Q, Li H, et al. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41854603. doi:10.1001/jamaoncol.2026.0318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。